These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31689461)

  • 61. Colonic delivery of carboxyfluorescein by pH-sensitive microspheres in experimental colitis.
    Kietzmann D; Moulari B; Béduneau A; Pellequer Y; Lamprecht A
    Eur J Pharm Biopharm; 2010 Oct; 76(2):290-5. PubMed ID: 20600885
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Exacerbated intestinal inflammation in P2Y
    Salem M; El Azreq MA; Pelletier J; Robaye B; Aoudjit F; Sévigny J
    Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2595-2605. PubMed ID: 31271845
    [TBL] [Abstract][Full Text] [Related]  

  • 63. COMP-angiopoietin-1 ameliorates inflammation-induced lymphangiogenesis in dextran sulfate sodium (DSS)-induced colitis model.
    Lee AS; Sung MJ; Kim W; Jung YJ
    J Mol Med (Berl); 2018 May; 96(5):459-467. PubMed ID: 29610929
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reciprocal regulation of the survival and apoptosis of Th17 and Th1 cells in the colon.
    Ustyugova IV; Zhi L; Wu MX
    Inflamm Bowel Dis; 2012 Feb; 18(2):333-43. PubMed ID: 21618360
    [TBL] [Abstract][Full Text] [Related]  

  • 65. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease.
    Beloqui A; Coco R; Memvanga PB; Ucakar B; des Rieux A; Préat V
    Int J Pharm; 2014 Oct; 473(1-2):203-12. PubMed ID: 25014369
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Orally Administrated Inflamed Colon-Targeted Nanotherapeutics for Inflammatory Bowel Disease Treatment by Oxidative Stress Level Modulation in Colitis.
    Min DK; Kim YE; Kim MK; Choi SW; Park N; Kim J
    ACS Nano; 2023 Dec; 17(23):24404-24416. PubMed ID: 38039189
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Calcitriol analog ZK191784 ameliorates acute and chronic dextran sodium sulfate-induced colitis by modulation of intestinal dendritic cell numbers and phenotype.
    Strauch UG; Obermeier F; Grunwald N; Dunger N; Rath HC; Schölmerich J; Steinmeyer A; Zügel U; Herfarth HH
    World J Gastroenterol; 2007 Dec; 13(48):6529-37. PubMed ID: 18161923
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Anti-tumor necrosis factor α therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis.
    Petito V; Graziani C; Lopetuso LR; Fossati M; Battaglia A; Arena V; Scannone D; Quaranta G; Quagliariello A; Del Chierico F; Putignani L; Masucci L; Sanguinetti M; Sgambato A; Gasbarrini A; Scaldaferri F
    World J Gastroenterol; 2019 Mar; 25(12):1465-1477. PubMed ID: 30948910
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Alginate/chitosan microcapsules for in-situ delivery of the protein, interleukin-1 receptor antagonist (IL-1Ra), for the treatment of dextran sulfate sodium (DSS)-induced colitis in a mouse model.
    Cao J; Cheng J; Xi S; Qi X; Shen S; Ge Y
    Eur J Pharm Biopharm; 2019 Apr; 137():112-121. PubMed ID: 30779979
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cyclosporine A-loaded lipid nanoparticles in inflammatory bowel disease.
    Guada M; Beloqui A; Alhouayek M; Muccioli GG; Dios-Viéitez Mdel C; Préat V; Blanco-Prieto MJ
    Int J Pharm; 2016 Apr; 503(1-2):196-8. PubMed ID: 26972380
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effective therapy of cyclosporine A with drug delivery system in experimental colitis.
    Fukata N; Uchida K; Kusuda T; Koyabu M; Miyoshi H; Fukui T; Matsushita M; Nishio A; Tabata Y; Okazaki K
    J Drug Target; 2011 Jul; 19(6):458-67. PubMed ID: 20804404
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy.
    Nakase H; Okazaki K; Tabata Y; Uose S; Ohana M; Uchida K; Matsushima Y; Kawanami C; Oshima C; Ikada Y; Chiba T
    J Pharmacol Exp Ther; 2000 Jan; 292(1):15-21. PubMed ID: 10604927
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Airway activation of formyl peptide receptors inhibits Th1 and Th17 cell responses via inhibition of mediator release from immune and inflammatory cells and maturation of dendritic cells.
    Tae YM; Park HT; Moon HG; Kim YS; Jeon SG; Roh TY; Bae YS; Gho YS; Ryu SH; Kwon HS; Kim YK
    J Immunol; 2012 Feb; 188(4):1799-808. PubMed ID: 22262660
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Oral Escherichia coli expressing IL-35 meliorates experimental colitis in mice.
    Zhang B; Liu Y; Lan X; Xu X; Zhang X; Li X; Zhao Y; Li G; Du C; Lu S; Wang H
    J Transl Med; 2018 Mar; 16(1):71. PubMed ID: 29554971
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Timosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balance.
    Lim SM; Jeong JJ; Kang GD; Kim KA; Choi HS; Kim DH
    Int Immunopharmacol; 2015 Apr; 25(2):493-503. PubMed ID: 25698557
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Regulation of T cell lineage commitment by SMAR1 during inflammatory & autoimmune diseases.
    Mirlekar B; Majumdar S; Khetmalas M; Chattopadhyay S
    Indian J Med Res; 2015 Oct; 142(4):405-13. PubMed ID: 26609032
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation.
    Kalim KW; Basler M; Kirk CJ; Groettrup M
    J Immunol; 2012 Oct; 189(8):4182-93. PubMed ID: 22984077
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines.
    Wilson DS; Dalmasso G; Wang L; Sitaraman SV; Merlin D; Murthy N
    Nat Mater; 2010 Nov; 9(11):923-8. PubMed ID: 20935658
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Delivery of tacrolimus with cationic lipid-assisted nanoparticles for ulcerative colitis therapy.
    Wang JL; Gan YJ; Iqbal S; Jiang W; Yuan YY; Wang J
    Biomater Sci; 2018 Jun; 6(7):1916-1922. PubMed ID: 29850666
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Exopolysaccharide-Producing
    Yu R; Zuo F; Ma H; Chen S
    Nutrients; 2019 Apr; 11(4):. PubMed ID: 30987344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.